Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

December 21, 2024

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.

Santhera Pharmaceuticals announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older.

- Follow Us -

Tags
AGAMREE
Hong Kong
Santhera
Vamorolone

Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Researchers Discover 18-Digit Code (Wnt7a) that Allows Proteins to Hitch a Ride Around the Body

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

Accredited Duchenne Centers (ADC) Aims to Provide Uniform and Up-to-date Care for All People Living with Duchenne Muscular Dystrophy

RGX-202 Gene Therapy Phase 3 Clinical Trial Begins

Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies

Wellcome Trust Donates £10 Million to Treat Rare Diseases

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.

LEAVE A REPLY Cancel reply

Hot Topics

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy: Treatment & Cost

Related Articles

Will Genethon and Eukarÿs Partnership Reduce the Cost of Gene Therapies?

20 Important Things You Need to Know About DMD Genetic Testing

Roche Announces New Results from the EMBARK Study of Elevidys in Outpatients with Duchenne Muscular Dystrophy (DMD)

About us

Latest Articles